In patients with metastatic TP53 hotspot-mutant NSCLC, antiangiogenic therapy provided significantly better clinical benefit and PFS than those with TP53- NSCLC, supporting the concept that TP53 mutations induce tumor angiogenesis [24, 25, 42–44]. This evidence concerns the gene TP53 and neoplasm.